AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
February 17, 2023 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIMイムノテック (AIM ImmunoTech)、アストラゼネカ (AstraZeneca) およびエラスムスメディカルセンター (Erasmus Medical Center) と、膵臓がんに関する臨床研究契約を締結
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
フロリダ州オカラ発, Jan. 17, 2023 (GLOBE NEWSWIRE) -- 複数のタイプのがんや免疫障害、ウイルス性疾患 (SARS-CoV-2ウイルスが原因で発症する新型コロナウイルス感染症を含む) の治療法の研究開発に注力する免疫製薬会社であるAIMイムノテック (AIM ImmunoTech Inc: AIM)...
AIM ImmunoTech与AstraZeneca和伊拉斯谟医疗中心签订胰腺癌临床研究协议
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所代码：AIM）（以下简称“AIM...
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
January 09, 2023 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
January 05, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
December 12, 2022 09:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
December 08, 2022 08:05 ET
|
AIM ImmunoTech Inc.
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral...
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
December 02, 2022 10:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...